Platelet cyclic adenosine monophosphate signaling pathway (Platelet cAMP signaling)

Platelet cAMP signaling is the primary endogenous inhibitory pathway that maintains platelets in a quiescent state within the healthy vasculature [1, 3]. It is primarily driven by endothelial-derived prostacyclin (PGI2), which binds to the Gs-coupled IP receptor on platelets, activating adenylate cyclase to produce cAMP [2, 6]. Elevated cAMP levels activate Protein Kinase A (PKA), which phosphorylates a variety of downstream targets, such as the IP3 receptor and VASP, to inhibit calcium mobilization, granule release, and the activation of the integrin alphaIIbbeta3 receptor [4, 7]. Conversely, platelet agonists like ADP act through Gi-coupled receptors (P2Y12) to decrease cAMP levels and promote activation [2, 12]. Pharmacological modulation of this pathway, through phosphodiesterase inhibitors (e.g., cilostazol) or P2Y12 antagonists (e.g., clopidogrel), is a cornerstone of antiplatelet therapy for preventing thrombotic events in cardiovascular disease [6, 14]. This signaling network is highly complex and involves compartmentalization by A-kinase anchoring proteins (AKAPs) to ensure precise control of platelet functions [3, 8].

Other names

cAMP-mediated platelet inhibitionPlatelet cAMP/PKA pathwayAdenylate cyclase pathway in platelets

Modulation of intracellular cyclic AMP levels to regulate Protein Kinase A activity and inhibit platelet activation pathways [1, 3, 6].